MC-Alkyl-Hydrazine Modified MMAF - CAS 1404071-64-2
  1. Home
  2. Products
  3. ADCs Cytotoxin with Linkers
  4. MC-Alkyl-Hydrazine Modified MMAF

MC-Alkyl-Hydrazine Modified MMAF - CAS 1404071-64-2 Catalog number: BADC-00592

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

MC-Alkyl-Hydrazine Modified MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine.

Category
ADCs Cytotoxin with Linkers
Product Name
MC-Alkyl-Hydrazine Modified MMAF
CAS
1404071-64-2
Catalog Number
BADC-00592
Molecular Formula
C59H92N10O12
Molecular Weight
1133.42
MC-Alkyl-Hydrazine Modified MMAF

Ordering Information

Catalog Number Size Price Quantity
BADC-00592 -- $--
Inquiry
Description
MC-Alkyl-Hydrazine Modified MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine.
Synonyms
N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]hydrazino}-4-oxobutyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S)-3-(1H-indol-3-yl)-1-(1,2-oxazinan-2-yl)-1-oxopropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide; N-(4-{2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]hydrazino}-4-oxobutyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S)-3-(1H-indol-3-yl)-1-{1,2-oxazinan-2-yl)-1-oxopropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
IUPAC Name
(2S)-2-[[(2S)-2-[[4-[2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl]hydrazinyl]-4-oxobutyl]-methylamino]-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(2S)-3-(1H-indol-3-yl)-1-(oxazinan-2-yl)-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
Canonical SMILES
O=C(N1CCCCO1)[C@@H](NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@@]([C@@H](C)CC)([H])N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCC(NNC(CCCCCN3C(C=CC3=O)=O)=O)=O)=O)=O)=O)OC)=O)CC4=CNC5=CC=CC=C45
InChI
InChI=1S/C59H92N10O12/c1-12-39(6)54(66(9)59(78)52(37(2)3)62-57(76)53(38(4)5)65(8)29-21-26-48(71)64-63-47(70)25-14-13-17-30-68-49(72)27-28-50(68)73)46(79-10)35-51(74)67-31-20-24-45(67)55(80-11)40(7)56(75)61-44(58(77)69-32-18-19-33-81-69)34-41-36-60-43-23-16-15-22-42(41)43/h15-16,22-23,27-28,36-40,44-46,52-55,60H,12-14,17-21,24-26,29-35H2,1-11H3,(H,61,75)(H,62,76)(H,63,70)(H,64,71)/t39-,40+,44-,45-,46+,52-,53-,54-,55+/m0/s1
Shipping
Room temperature
1.Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs.
Samantha Congreve, Reham Faris Elias, Gabriel Tidestav, Venus Zafrianian
A literature study was performed on a new type of cancer medicine:antibody drug conjugates, or ADCs. These consist of a monoclonalantibody, chemically linked to a cytotoxic agent. What makes themunique is their selective toxicity against cancer cells. The firstapproval of such a pharmaceutical was in the year 2000, with three orfour available in different regions of the world today. In the rangeof 50 registered drugs in clinical development were found, by majorand minor corporations. These have been presented in a table in theappendix according to their properties such as type of linker,cytotoxin, development status etc. Furthermore, a detailed study hasbeen done of the chemistry of the linker conjugation as well as anattempt at studying the ADC market. Finally, the mentioned strengthsof the drug were compared to its weaknesses, mainly instability andotherwise poor pharmacokinetics. The main conclusion is that thesedrugs are expected to play a major role in oncology in the future.
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Calculate
The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Calculate

Related Products

Azido-PEG4-Glu-Val-Cit-PAB-MMAE
Azido-PEG4-Glu-Val-Cit-PAB-MMAE
BA-3011
BA-3011
SPB
SPB
(CAS: 858128-57-1)
Mc-Dexamethasone
Mc-Dexamethasone
(CAS: 1618096-56-2)
DGN549-C
DGN549-C
(CAS: 2058075-34-4)
MC-Val-Cit-PAB-MMAE
MC-Val-Cit-PAB-MMAE
(CAS: 646502-53-6)
Historical Records: Azido-PEG5-alcohol | MC-Alkyl-Hydrazine Modified MMAF
Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Featured Services
cGMP Grade Products

BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
Site-Specific Conjugation

BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
Linkers for Bioconjugation

BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
ADC Targets
Questions & Comments
Verification code
Send Inquiry
Verification code
Inquiry Basket
loading Loading ......
Delete selectedGo to checkout